Eli Lilly and Company Stock News

INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D.

President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs.  Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.

Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month  INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solu...

The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their weight-loss drugs.

President Donald Trump announced a landmark agreement Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to dramatically slash prices for their blockbuster weight-loss drugs, potentially cutting monthly costs from over $1,300 to as low as $149.

President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments.  The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration...

President Donald Trump's administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration's new direct-to-consumer website.

Eli Lilly said on Thursday its experimental obesity drug helped patients lose as much as 20.1% of their weight in a mid-stage trial.